Compare KELYB & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | IRWD |
|---|---|---|
| Founded | 1946 | 1998 |
| Country | United States | United States |
| Employees | 5570 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.9M | 526.7M |
| IPO Year | N/A | 2009 |
| Metric | KELYB | IRWD |
|---|---|---|
| Price | $15.59 | $3.56 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.94 |
| AVG Volume (30 Days) | 16.6K | ★ 2.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $0.72 | $57.95 |
| Revenue Next Year | N/A | $4.39 |
| P/E Ratio | ★ N/A | $24.13 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $8.38 | $0.55 |
| 52 Week High | $125.00 | $5.78 |
| Indicator | KELYB | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 57.66 | 52.13 |
| Support Level | $11.66 | $3.07 |
| Resistance Level | $21.46 | $3.92 |
| Average True Range (ATR) | 1.00 | 0.21 |
| MACD | 0.32 | 0.07 |
| Stochastic Oscillator | 53.86 | 63.89 |
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services to a diverse group of clients operating in the Americas, Europe, and the Asia-Pacific region across various industries. The company's reportable segments are: Enterprise Talent Management, Science, Engineering and Technology, and Education. Maximum revenue is generated from its Enterprise Talent Management segment, which delivers temporary staffing, outcome-based, and permanent placement services focused on light industrial, contact center, and office and clerical specialties in North America across various industries. It also provides talent supply chain and workforce talent solutions, including MSP, RPO, and PPO solutions to its clients. Geographically, it derives key revenue from the USA.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.